|
A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical research trials and A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus. A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus clinical trial. Participants oftentimes recieve the most expert healthcare available for their A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus  A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
For Condition: Diabetes
Status: Completed
Sponsor(s): Hoffmann-La Roche ,
Synopsis: The objectives of the study are: To determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 5 to 20 mg/day will be studied.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 35 Years/75 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Age 35 to 75 - Type 2 diabetes for longer than 3 months - HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening - FPG (fasting plasma glucose) greater than 126 mg/dL at screening - BMI (body mass index) less than 40 kg/square meter Exclusion Criteria: - Type I diabetes - Type 2 diabetes patients currently treated with insulin - Type 2 diabetes patients curently or previously treated with Actos, Avandia or Rezulin - FPG (fasting plasma glucose) greater than 270 mg/dL at baseline - Impaired liver or kidney function - Triglycerides greater than 600 mg/dL - Uncontrolled hypertension - Pregnant or lactating women - Women not using adequate contraception
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: WM16177;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00057317
Other Diabetes Studies:
1. Comparative Efficacy Evaluation of Lipids when Treated with Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
2. A Multicenter Study to Evaluate Retisert in the Treatment of Patients with Diabetic Macular Edema
3. Differential Metabolism of Dietary Fatty Acids
4. Improving Health Outcomes of Diabetic Veterans: A Diabetic Self-Management Program
5. A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
Related Studies:
Other Diabetes Clinical Trials
Other New York Clinical Trials
Other New Hyde Park Clinical Trials
A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
|
|
|
|
|
|
|
|
